Asthma attacks: how can we reduce the risks?
作者信息
Thomas Mike, Bateman Eric
机构信息
Department of Primary Care Research, University of Southampton and Aldermoor Health Centre, Southampton, UK.
Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, Republic of South Africa.
出版信息
NPJ Prim Care Respir Med. 2015 Jan 8;25:14105. doi: 10.1038/npjpcrm.2014.105.
Abstract
摘要
相似文献
1
Asthma attacks: how can we reduce the risks?哮喘发作：我们如何降低风险？
NPJ Prim Care Respir Med. 2015 Jan 8;25:14105. doi: 10.1038/npjpcrm.2014.105.
2
Reducing asthma attacks: consider patients' beliefs.减少哮喘发作：考虑患者的信念。
NPJ Prim Care Respir Med. 2015 Apr 2;25:15021. doi: 10.1038/npjpcrm.2015.21.
3
Real-life use of budesonide/formoterol in clinical practice: a 12-month follow-up assessment in a multi-national study of asthma patients established on single-inhaler maintenance and reliever therapy.布地奈德/福莫特罗在临床实践中的实际应用：一项针对采用单吸入器维持和缓解治疗的哮喘患者进行的多国研究的12个月随访评估。
Int J Clin Pharmacol Ther. 2015 Jun;53(6):447-55. doi: 10.5414/CP202224.
4
The use of β2-agonist therapy before hospital attendance for severe asthma exacerbations: a post-hoc analysis.β2-激动剂治疗在严重哮喘恶化患者住院前的应用：一项事后分析。
NPJ Prim Care Respir Med. 2015 Jan 8;25:14099. doi: 10.1038/npjpcrm.2014.99.
5
Budesonide/formoterol in the treatment of asthma.布地奈德/福莫特罗治疗哮喘。
Expert Rev Respir Med. 2010 Oct;4(5):557-66. doi: 10.1586/ers.10.60.
6
Comparative effectiveness of budesonide-formoterol combination and fluticasone-salmeterol combination for asthma management: a United States retrospective database analysis.布地奈德-福莫特罗联合制剂与氟替卡松-沙美特罗联合制剂治疗哮喘的疗效比较：一项美国回顾性数据库分析。
J Allergy Clin Immunol Pract. 2014 Nov-Dec;2(6):719-26. doi: 10.1016/j.jaip.2014.07.016. Epub 2014 Oct 3.
7
Budesonide/formoterol pressurized metered-dose inhaler for patients with persistent asthma.布地奈德/福莫特罗压力型定量吸入器治疗持续性哮喘患者。
Allergy Asthma Proc. 2010 May-Jun;31(3):190-202. doi: 10.2500/aap.2010.31.3356.
8
Serious Asthma Events with Budesonide plus Formoterol vs. Budesonide Alone.布地奈德联用福莫特罗与单用布地奈德治疗严重哮喘事件的比较。
N Engl J Med. 2016 Sep 1;375(9):850-60. doi: 10.1056/NEJMoa1511190.
9
Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma.布地奈德/福莫特罗维持加缓解治疗：小儿哮喘的一种新策略。
Chest. 2006 Dec;130(6):1733-43. doi: 10.1378/chest.130.6.1733.
10
Increasing doses of inhaled corticosteroids compared to adding long-acting inhaled beta2-agonists in achieving asthma control.与添加长效吸入型β2受体激动剂相比，增加吸入性糖皮质激素剂量在实现哮喘控制方面的效果。
Chest. 2008 Dec;134(6):1192-1199. doi: 10.1378/chest.08-1018. Epub 2008 Aug 8.
引用本文的文献
1
Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged ≥4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study.按需沙丁胺醇/布地奈德与沙丁胺醇治疗 4 岁及以上中重度哮喘成人和儿童患者的疗效和安全性：随机、双盲、阳性对照 MANDALA 研究的原理和设计。
BMJ Open Respir Res. 2021 Dec;8(1). doi: 10.1136/bmjresp-2021-001077.
2
Living with asthma and chronic obstructive airways disease: Using technology to support self-management - An overview.患有哮喘和慢性阻塞性气道疾病：使用技术支持自我管理-概述。
Chron Respir Dis. 2017 Nov;14(4):407-419. doi: 10.1177/1479972316660977. Epub 2016 Aug 10.
3
Reducing asthma attacks: consider patients' beliefs.减少哮喘发作：考虑患者的信念。
NPJ Prim Care Respir Med. 2015 Apr 2;25:15021. doi: 10.1038/npjpcrm.2015.21.
本文引用的文献
1
The use of β2-agonist therapy before hospital attendance for severe asthma exacerbations: a post-hoc analysis.β2-激动剂治疗在严重哮喘恶化患者住院前的应用：一项事后分析。
NPJ Prim Care Respir Med. 2015 Jan 8;25:14099. doi: 10.1038/npjpcrm.2014.99.
2
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma.国际 ERS/ATS 指南：严重哮喘的定义、评估和治疗。
Eur Respir J. 2014 Feb;43(2):343-73. doi: 10.1183/09031936.00202013. Epub 2013 Dec 12.
3
Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial.有发生严重恶化风险的哮喘患者使用布地奈德/福莫特罗维持和缓解联用吸入器的疗效和安全性：一项随机对照试验。
Lancet Respir Med. 2013 Mar;1(1):32-42. doi: 10.1016/S2213-2600(13)70007-9. Epub 2013 Mar 4.
4
Accuracy of patient self-report as a measure of inhaled asthma medication use.患者自我报告作为吸入性哮喘药物使用的衡量标准的准确性。
Respirology. 2013 Apr;18(3):546-52. doi: 10.1111/resp.12059.
5
Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children.长效β2受体激动剂与相同剂量吸入性糖皮质激素联合应用于成人及儿童慢性哮喘的疗效比较
Cochrane Database Syst Rev. 2010 May 12(5):CD005535. doi: 10.1002/14651858.CD005535.pub2.
6
Inhaled corticosteroids and hospitalisation due to exacerbation of COPD.吸入性糖皮质激素与慢性阻塞性肺疾病急性加重导致的住院治疗
Eur Respir J. 2003 Aug;22(2):286-9. doi: 10.1183/09031936.03.00113802.
7
Self-management education and regular practitioner review for adults with asthma.针对成年哮喘患者的自我管理教育及定期医生复查
Cochrane Database Syst Rev. 2003(1):CD001117. doi: 10.1002/14651858.CD001117.
8
Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group.哮喘急性加重：425例严重急性加重的描述性研究。FACET国际研究小组。
Am J Respir Crit Care Med. 1999 Aug;160(2):594-9. doi: 10.1164/ajrccm.160.2.9811100.
9
Patterns of increasing beta-agonist use and the risk of fatal or near-fatal asthma.β受体激动剂使用增加模式与致命或近乎致命哮喘的风险
Eur Respir J. 1994 Sep;7(9):1602-9. doi: 10.1183/09031936.94.07091602.
Zotero 插件